ABIONYX Unlocks Biomanufacturing Key for Sepsis, Rare Diseases

TOULOUSE, France – March 27, 2026 – ABIONYX Pharma saw its shares surge over 23% today after announcing a pivotal breakthrough in its manufacturing process that could significantly alter the treatment landscape for sepsis and a rare genetic disorder. The biopharmaceutical company has mastered the industrial-scale production of an ultra-pure, synthetic version of sphingomyelin, a critical component of its lead therapeutic candidate, CER-001.

This development is more than a simple process improvement; it represents the overcoming of a major technological barrier in producing complex biologic drugs. By tripling the production yield and ensuring unprecedented purity, ABIONYX has not only enhanced the safety and scalability of CER-001 but has also strategically positioned itself as a leader in advanced biomanufacturing, a capability highly coveted within the pharmaceutical industry.

The Science of a Safer, Scalable Biologic

At the heart of the announcement is CER-001, a bio-inspired drug designed to mimic the function of natural high-density lipoprotein (HDL), often called “good cholesterol.” The drug consists of two key components: the apoA-I protein and a complex lipid shell. Sphingomyelin is a strategic lipid within that shell, essential for stabilizing the protein and giving the drug its therapeutic properties.

Traditionally, sphingomyelin has been sourced from animal products like eggs or bovine tissue, a practice fraught with challenges. These natural sources carry risks of biological contamination, potential allergenic reactions, and inherent batch-to-batch variability, creating significant hurdles for pharmaceutical manufacturing where consistency and safety are paramount.

ABIONYX's innovation lies in its proprietary, patented method for creating a 100% synthetic sphingomyelin. This move completely eliminates the reliance on animal sources, thereby nullifying contamination and allergen risks. More importantly, the synthetic process allows for a component of exceptional purity and defined structural quality, meeting the most stringent regulatory standards. The company reports its synthetic version is also intrinsically more stable, reducing the need for added stabilizers and further bolstering manufacturing robustness.

Furthermore, the new process achieves a threefold increase in production yield. This leap in efficiency is critical, transforming the potential of CER-001 from a niche, difficult-to-produce biologic into a therapy that can be manufactured at the scale required for widespread clinical use.

A Two-Pronged Attack on Unmet Medical Needs

The manufacturing breakthrough has profound strategic implications for the two primary diseases ABIONYX is targeting with CER-001: the rare genetic disorder LCAT deficiency and the global health crisis of sepsis.

For patients with LCAT deficiency—a disease that disrupts lipid metabolism and can lead to kidney failure—treatment options are scarce and largely symptomatic. ABIONYX is on a path toward seeking Marketing Authorization (MAA) for CER-001 to treat this condition. A crucial step in this regulatory journey is the production of “validation batches” of the drug to prove to agencies like the FDA and EMA that manufacturing is consistent, controlled, and reliable. The new synthetic process directly de-risks this critical milestone, ensuring a secure supply of high-purity, reproducible material and potentially accelerating the drug's path to patients.

In the case of sepsis, the stakes are even higher. Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, and it remains a leading cause of death in hospitals worldwide with no specific approved therapies. The market is vast, but it demands a therapy that can be produced reliably and in very large quantities. The newfound scalability of CER-001 production directly addresses this challenge. By combining highly purified apoA-I with its proprietary synthetic sphingomyelin, ABIONYX is positioned to deliver a differentiated therapy aimed at restoring essential biological functions in critically ill sepsis patients, a goal that has eluded many drug developers.

More Than a Drug: A Platform for Growth

While the immediate focus is on CER-001, the implications of this technological achievement extend far beyond a single product. ABIONYX has effectively established a best-in-class biomanufacturing platform, demonstrating an ability to control and produce complex biologics at an unprecedented level of quality and scale.

The proprietary synthetic sphingomyelin itself is now a valuable asset. The company has noted its potential use in other pharmaceutical applications, such as in advanced drug delivery systems like liposomes, where purity and stability are highly valued. Beyond medicine, the high-end cosmetics industry is another potential market, as sphingomyelin is a prized ingredient in advanced skincare for its ability to support the skin's natural barrier.

This diversification of intellectual property opens new avenues for revenue through strategic partnerships or licensing deals with other pharmaceutical and cosmetic companies. It signals a maturation of ABIONYX from a pure-play drug developer into a more integrated biopharmaceutical entity with valuable, proprietary manufacturing technology.

This milestone reinforces the company's industrial scalability and strengthens its supply chain, providing a solid foundation for upcoming clinical and regulatory milestones. By solving a fundamental production challenge, ABIONYX has not only brightened the prospects for its own pipeline but has also set a new standard for the manufacturing of complex lipid-based therapeutics.